Bilaal.Raja
Company record

PLSE  PULSE BIOSCIENCES, INC.

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$3.4bn
Revenue TTM
$1m
Net income TTM
$-80m
Free cash flow
$-61m
Composite score
—
Sector rank
#1272

Valuation

P / E
—
EV / EBITDA
—
EV / sales
2,797.2
FCF yield
-1.80%
Yield vs 10-yr
-7.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6,755.8%
EBITDA margin
-6,920.5%
ROE
-80.5%
ROIC
—
Revenue growth
—

Insider activity, last 90 days

Net open-market
$0.20m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In developing this guidance, the Company’s management must make certain assumptions and judgments about its future operating performance, including but not limited to projected hiring of sales and marketing professionals, growth of revenue in the relevant device markets, increase or decrease of its market share, costs of production of its recently introduced products, and stability of the macro-economic environment in the Company’s key markets.PULSE BIOSCIENCES, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →